These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34080542)

  • 1. Pre-exposure prophylaxis awareness, acceptability and potential stigma among medical and non-medical clinic staff in methadone treatment settings in northern New Jersey: The key role of non-medical staff in enhancing HIV prevention.
    Jaiswal J; Dunlap K; Griffin M; Cox A; Singer SN; Hascher K; LoSchiavo C; Walters SM; Mumba M
    J Subst Abuse Treat; 2021 Oct; 129():108371. PubMed ID: 34080542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Logistical Facilitators and Barriers to PrEP Implementation in Methadone Clinic Settings: Provider and Staff Perspectives.
    Jaiswal J; Griffin M; Hascher K; Cox AB; Dunlap K; Walters S; LoSchiavo C; Burton WM; Mumba M
    J Addict Med; 2022 Sep-Oct 01; 16(5):e278-e283. PubMed ID: 35165229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges to Providing Integrated HIV Prevention in Substance Use Treatment Settings: Frontline Staff Perspectives on HIV and Sex-Related, Education, Communication and Stigma.
    Jaiswal J; Griffin M; LoSchiavo C; Cox A; Hascher K; Dunlap K; Walters S; Burton WM; Grin B; Mumba M; Eaton E
    Subst Use Misuse; 2023; 58(14):1866-1873. PubMed ID: 37818832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.
    Shrestha R; Karki P; Altice FL; Huedo-Medina TB; Meyer JP; Madden L; Copenhaver M
    Drug Alcohol Depend; 2017 Apr; 173():107-116. PubMed ID: 28214391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users.
    Shrestha R; Karki P; Altice FL; Dubov O; Fraenkel L; Huedo-Medina T; Copenhaver M
    AIDS Behav; 2018 Apr; 22(4):1228-1238. PubMed ID: 28695388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment.
    Ni Z; Altice FL; Wickersham JA; Copenhaver MM; DiDomizio EE; Nelson LE; Shrestha R
    Drug Alcohol Depend; 2021 Feb; 219():108477. PubMed ID: 33422864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: implications for PrEP adoption among Latino men who have sex with men.
    Brooks RA; Nieto O; Landrian A; Donohoe TJ
    AIDS Care; 2019 Apr; 31(4):427-435. PubMed ID: 30021456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Hershow RB; Gonzalez M; Costenbader E; Zule W; Golin C; Brinkley-Rubinstein L
    AIDS Educ Prev; 2019 Aug; 31(4):363-379. PubMed ID: 31361517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review.
    Bradley E; Forsberg K; Betts JE; DeLuca JB; Kamitani E; Porter SE; Sipe TA; Hoover KW
    J Womens Health (Larchmt); 2019 Sep; 28(9):1272-1285. PubMed ID: 31180253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considering Stigma in the Provision of HIV Pre-Exposure Prophylaxis: Reflections from Current Prescribers.
    Calabrese SK; Tekeste M; Mayer KH; Magnus M; Krakower DS; Kershaw TS; Eldahan AI; Gaston Hawkins LA; Underhill K; Hansen NB; Betancourt JR; Dovidio JF
    AIDS Patient Care STDS; 2019 Feb; 33(2):79-88. PubMed ID: 30715918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa.
    Nyblade L; Ndirangu JW; Speizer IS; Browne FA; Bonner CP; Minnis A; Kline TL; Ahmed K; Howard BN; Cox EN; Rinderle A; Wechsberg WM
    BMC Public Health; 2022 Oct; 22(1):1916. PubMed ID: 36242000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PrEP facilitators and barriers in substance use bridge clinics for women who engage in sex work and who use drugs.
    Harris MT; Weinberger E; O'Brien C; Althoff M; Paltrow-Krulwich S; Taylor JL; Judge A; Samet JH; Walley AY; Gunn CM
    Addict Sci Clin Pract; 2024 Jun; 19(1):47. PubMed ID: 38831359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure.
    Walters SM; Frank D; Van Ham B; Jaiswal J; Muncan B; Earnshaw V; Schneider J; Friedman SR; Ompad DC
    AIDS Behav; 2022 Apr; 26(4):1308-1320. PubMed ID: 34626265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinic-Level Strategies for Mitigating Structural and Interpersonal HIV Pre-Exposure Prophylaxis Stigma.
    Price DM; Unger Z; Wu Y; Meyers K; Golub SA
    AIDS Patient Care STDS; 2022 Mar; 36(3):115-122. PubMed ID: 35289691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care.
    Pilgrim N; Jani N; Mathur S; Kahabuka C; Saria V; Makyao N; Apicella L; Pulerwitz J
    PLoS One; 2018; 13(4):e0196280. PubMed ID: 29702659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discomfort discussing HIV/AIDS and lack of awareness are barriers to partner-to-partner pre-exposure prophylaxis education.
    Farthing H; Rodriguez A; Armstrong M; Iyengar S; Nigh E; Potter J; Doblecki-Lewis S
    Int J STD AIDS; 2019 Feb; 30(2):147-153. PubMed ID: 30301426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment.
    Shrestha R; Altice FL; Huedo-Medina TB; Karki P; Copenhaver M
    AIDS Behav; 2017 May; 21(5):1299-1308. PubMed ID: 27990587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adolescent-Centered HIV Prevention: Perspectives on Acceptability of Oral Antiretroviral Pre-exposure Prophylaxis for Adolescents in a Global Priority Setting.
    Giovenco D; Kuo C; Underhill K; Hoare J; Operario D
    Arch Sex Behav; 2021 Oct; 50(7):2921-2931. PubMed ID: 34561792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.